NCT00411554View on ClinicalTrials.gov

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

319

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG

sitagliptin phosphate

sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks

DRUG

Comparator: voglibose

voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00411554 - A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED) | Biotech Hunter | Biotech Hunter